Monday, September 15, 2025 9/15/2025

2/2 Milrinone for Prevention of Post-Patent Ductus Arteriosus Closure Syndrome in Extremely Preterm Infants (MIDAS Trial) - DCC Resubmission

Award Number: U24HL166580
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2024
PERIOD OF PERFORMANCE END DATE: 06/30/2029

Group Awards By:

View Award Description

2/2 Milrinone for Prevention of Post-Patent Ductus Arteriosus Closure Syndrome in Extremely Preterm Infants (MIDAS Trial) - DCC Resubmission - Project Summary Infants born preterm are exposed to an array of morbidities. The most common cardiovascular problem observed in this population is patent ductus arteriosus (PDA). Following surgical closure of a PDA, infants can develop Post-Ligation Cardiac Syndrome (PLCS), a serious complication which represents a state of severe postoperative cardiopulmonary instability. PLCS can be observed in up to 50% of extremely premature infants after surgical closure of the PDA. Recognition and treatment of PLCS often occurs late and treatment is variable across hospitals. To date, there have been no randomized controlled clinical trials (RCTs) of cardiovascular drugs to either prevent or treat PLCS in preterm infants. Given the variance in treatment of PLCS, the potential use of harmful treatments amid suboptimal evidence or scientifically proven justification for use, a masked, multicenter randomized trial is essential. Preliminary data suggest that milrinone, a commonly used cardiovascular medication, reduces the risk of PLCS in neonates requiring surgical ligation for PDA. The proposed Milrinone for Prevention of Post-ligation Cardiac Syndrome (MIDAS) trial aims to move preliminary research forward by designing and implementing an RCT to obtain additional data to determine efficacy of prophylactic milrinone at reducing the incidence of PLCS and improving neonatal outcomes. We will apply the experience and rigor of the Neonatal Research Network infrastructure in performing randomized placebo-controlled trials in union with RTI’s leadership in statistical design and analysis and numerous prior successes in the development and implementation of RCTs. The specific aims for the MIDAS trial are: • Specific Aim #1: Determine the efficacy of prophylactic milrinone on decreasing PLCS and mortality in extremely preterm infants, born at gestational age <27 weeks and 6 days, after PDA closure by surgical ligation or percutaneous cardiac catheterization. • Subsidiary Aim: Determine the effects of prophylactic milrinone on 2-year survival and incidence of adverse neurodevelopmental outcomes in extremely preterm infants treated with PDA ligation. With successful execution of these planned experimental aims, the DCC will be able to contribute toward identification of an evidence-based approach (demonstrative of external validity and reproducibility) for the safe prevention and treatment of PCLS in preterm infants.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,221,243 )
2025	2025	RESEARCH TRIANGLE INSTITUTE	3040 CORNWALLIS RD	DURHAM	NC	27709	DURHAM	USA	Cardiovascular Diseases Research	000	2	8/5/2025	NON-COMPETING CONTINUATION	$1,221,243
														Subtotal = $1,221,243

Issue Date FY: 2024 ( Subtotal = $1,172,434 )
2024	2024	RESEARCH TRIANGLE INSTITUTE	3040 CORNWALLIS RD	DURHAM	NC	27709	DURHAM	USA	Cardiovascular Diseases Research	000	1	6/25/2024	NEW	$1,172,434
														Subtotal = $1,172,434

Grand Total All Awards = $2,393,677

Top

All Categories

About

Search

Reports

Data Submission

Award Information

2/2 Milrinone for Prevention of Post-Patent Ductus Arteriosus Closure Syndrome in Extremely Preterm Infants (MIDAS Trial) - DCC Resubmission

Award Number: U24HL166580

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2024

PERIOD OF PERFORMANCE END DATE: 06/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer